Arctium lappa extract
CAS 84012-13-5
Arctium lappa extract (CAS 84012-13-5) is a pharmaceutical compound with 0 bioactivity targets and 14 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Arctium lappa extract is linked to DTXSID901036479 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Arctium lappa extract used for in pharmaceutical contexts?
Arctium lappa extract (CAS 84012-13-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Arctium lappa extract?
Arctium lappa extract has 14 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Acidosis hyperchloraemic, Bradycardia, Diarrhoea, Dizziness, Electrolyte depletion. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Arctium lappa extract also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Burdock Oil with EU status "permitted".
What clinical phase is Arctium lappa extract in?
No phase 1-4 clinical development badge is rendered for Arctium lappa extract because the matched compound identifier rows do not contain a max-phase value.